Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Investing Activities (2016 - 2025)

Ligand Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at -$18.1 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 53.13% year-over-year to -$18.1 million; the TTM value through Dec 2025 reached -$377.3 million, down 162.64%, while the annual FY2025 figure was -$377.3 million, 162.64% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$18.1 million at Ligand Pharmaceuticals, up from -$353.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $113.9 million in Q1 2022 and bottomed at -$353.4 million in Q3 2025.
  • The 5-year median for Cash from Investing Activities is -$8.8 million (2022), against an average of -$16.9 million.
  • The largest annual shift saw Cash from Investing Activities crashed 824.71% in 2024 before it surged 229.64% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$35.7 million in 2021, then soared by 79.6% to -$7.3 million in 2022, then tumbled by 41.19% to -$10.3 million in 2023, then tumbled by 275.56% to -$38.6 million in 2024, then surged by 53.13% to -$18.1 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cash from Investing Activities are -$18.1 million (Q4 2025), -$353.4 million (Q3 2025), and -$10.7 million (Q2 2025).